Edition:
United States

Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

7.08USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$7.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,201,427
52-wk High
$11.69
52-wk Low
$4.50

Latest Key Developments (Source: Significant Developments)

Inovio launches Zika vaccine trial
Monday, 29 Aug 2016 07:00am EDT 

Inovio Pharmaceuticals Inc : Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy . Expects to report results before end of this year .Is developing its Zika vaccine, GLS-5700, with Geneone Life Science, Inc. And academic collaborators from US and Canada.  Full Article

Inovio Pharmaceuticals Q2 loss per share $0.26
Monday, 8 Aug 2016 08:00am EDT 

Inovio Pharmaceuticals Inc : Inovio Pharmaceuticals reports 2016 second quarter financial results . Q2 revenue $6.2 million versus $5.3 million . Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.26 .Q2 revenue view $5 million -- Thomson Reuters I/B/E/S.  Full Article

Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial
Tuesday, 26 Jul 2016 10:28am EDT 

Inovio Pharmaceuticals Inc: Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial . Center phase I trial to evaluate inovio's Zika dna vaccine . Says expect to complete subject dosing and report interim phase I results later this year .Health Canada's Health Products and Food Branch has also approved co's Zika study.  Full Article

Inovio, Geneone Life Science get approval to test Zika vaccine on humans
Monday, 20 Jun 2016 07:00am EDT 

Inovio Pharmaceuticals : Inovio Pharmaceuticals and Geneone Life Science have received approval to initiate a phase i human trial to evaluate it's Zika DNA vaccine .Inovio Pharmaceuticals And Geneone Life Science Receive Approval For First In-Man Zika vaccine clinical trial.  Full Article

Inovio Pharmaceuticals says stock offering of up to $50 mln - SEC Filing
Friday, 17 Jun 2016 05:00pm EDT 

Inovio Pharmaceuticals Inc :May offer and sell shares of common stock having aggregate offering price of up to $50 million through Stifel as sales agent.  Full Article

Inovio Pharmaceuticals reports Q1 loss of $0.11 per share
Monday, 9 May 2016 07:50am EDT 

Inovio Pharmaceuticals Inc : First clinical study of Inovio's zika vaccine is on track to start in 2016 . Inovio Pharmaceuticals reports 2016 first quarter financial results . Q1 loss per share $0.11 . Q1 revenue $8.1 million versus $5.2 million . Q1 revenue view $4.7 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.  Full Article

Inovio Pharmaceuticals, Inc acquires Needle-Free Injection Technology
Monday, 14 Mar 2016 08:01am EDT 

Inovio Pharmaceuticals, Inc:Says signed definitive agreement to acquire all of Bioject Medical Technologies Inc.'s assets including pioneering needle-free jet injection technology, devices, and intellectual property.Inovio will pay Bioject $5.5 million in cash and stock.  Full Article

GeneOneLifeScience and Inovio Pharmaceuticals' MERS Vaccine Approved
Thursday, 19 Nov 2015 09:00am EST 

GeneOneLifeScience:Says U.S. food and drug administration has cleared first-in-human clinical study of its collaborative vaccine for MERS.Says CO and Inovio Pharmaceuticals co-developing vaccine and plan to initiate first human trial of MERS vaccine before end of year.  Full Article

Inovio Pharmaceuticals Inc successful phase 2b trial results of its hpv immunotherapy in the lancet
Thursday, 17 Sep 2015 08:00am EDT 

Inovio Pharmaceuticals Inc:Publishes successful phase 2b trial results of its hpv immunotherapy in the lancet.Vgx-3100 is first therapy to demonstrate activated killer t cells induced in body have power to clear neoplastic lesions.Data showed histopathological regression of high grade cervical neoplasia to low grade neoplasia,no disease in higher percent in vgx-3100 arm.Concomitant histopathological regression,clearance of hpv occurred in a significantly higher percentage of vgx-3100 recipients.In vgx-3100-treated women who regressed their lesion, most (43 out of 53) completely cleared their lesions to normal.  Full Article

Inovio Pharmaceuticals Inc enters into strategic cancer vaccine collaboration with Medimmune
Monday, 10 Aug 2015 03:00am EDT 

Inovio Pharmaceuticals Inc:Enters into strategic cancer vaccine collaboration and license agreement with Medimmune.Agreement includes clinical-stage ino-3112 hpv cancer vaccine and preclinical collaboration to develop additional cancer vaccine candidates.Medimmune will make an upfront payment of $27.5 mln to Inovio as well as potential future payments upon reaching milestones up to $700 mln.Medimmune intends to study ino-3112 in combination with selected immunotherapy molecules within its pipeline in hpv-driven cancers.Says under the agreement, Medimmune will acquire exclusive rights to inovio's ino-3112 immunotherapy.  Full Article

BRIEF-Inovio's cancer immunotherapy generates T cell immune responses in tumor tissue and peripheral blood in patients with HPV-associated head and neck cancer

* Inovio's cancer immunotherapy (INO-3112) generates t cell immune responses in tumor tissue and peripheral blood in patients with HPV-associated head and neck cancer